Back

The nuclear speckles protein SRRM2 is a new therapeutic target molecule on the surface of cancer cells

Kellner, M.; Hoermann, J.; Fackler, S.; Yuanyu, H.; Lin, L.; Ilik, I.; Aktas, T.; Feederle, R.; Hauck, S. M.; Gires, O.; Gaertner, K.; Lietao, L.; Zeidler, R.

2024-04-27 cancer biology
10.1101/2024.04.26.591288 bioRxiv
Show abstract

The membrane composition of extracellular vesicles (EVs) largely reflects that of the plasma membrane of the cell of origin. We therefore hypothesized that EVs are a source for the detection of hitherto unknown tumor-associated druggable target molecules. For this, we used EVs derived from cancer cell lines for an immunization of a rat. From this immunization, we obtained a monoclonal antibody specific for SRRM2, a protein involved in splicing a major component of nuclear speckles. Here, we used this antibody to demonstrate that SRRM2 is exposed at the surface of most cancer cell lines from various entities and, even more important, on cancer cells in vivo. Moreover, we demonstrate that SRRM2-specific CAR-T cells are killing SRRM2-positive cancer cells electively. Collectively, we identified SRRM2 as a promising new target molecule exposed on the cancer cell surface and show that our SRRM2-specific antibody can be used as a basis for the development of new targeted cancer therapies.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.